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A B S T R A C T
Purpose: The gamma-aminobutyric acid A receptor, gamma 2 (GABRG2) gene encodes the GABRg2
protein, which has been implicated in susceptibility to epilepsy. Several studies have examined a
possible link between the exonic GABRG2 rs211037 locus and susceptibility to febrile seizure (FS) and
idiopathic generalized epilepsy (IGE), however results have been inconclusive. We therefore performed a
systematic review and meta-analysis to examine whether this polymorphism is associated with FS or
IGE.
Methods: Eight studies comprising 1871 epilepsy patients and 1387 controls, which evaluated
association of the GABRG2 rs211037 polymorphism with susceptibility to epilepsy, were included in this
meta-analysis. Meta-analysis was carried out separately for FS and IGE.
Results: Meta-analysis showed a signiﬁcant association between this polymorphism and susceptibility
to FS in a codominant (TT vs. CC, OR 0.47, 95% CI 0.30–0.73, p = 0.0008 and TT vs. CT, OR 0.59, 95% CI 0.42–
0.83, p = 0.003) and dominant (OR 0.54, 95% CI 0.39–0.75, p = 0.0002) genetic models, inﬂuenced by two
studies with small sample size. Neither allele nor genotype association was observed with IGE.
Conclusion: This study showed signiﬁcant association of GABRG2 rs211037 with susceptibility to FS,
caused by two studies with small sample sizes, however the possibility of false positive results due to the
effect of signiﬁcant studies for FS cannot be excluded. Future studies with larger sample sizes of these
patients are suggested to verify the results.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Gamma-aminobutyric acid (GABA) is a major inhibitory
neurotransmitter in the central nervous system. This molecule
exerts its function primarily through several receptors, including
GABA-A. The GABA-A receptor is part of a ligand-gated ion channel
complex which allows chloride ions to enter neurons, resulting in
hyperpolarization that reduces the probability of an action
potential. The GABA-A receptor is the most common receptor in
the mammalian brain and mediates a majority of fast synaptic
inhibition.1 The GABA-A receptor is pentameric and consists of two
a, two b, and one g subunits, with the most common subunit
composition being a1, b2, and g2, encoded by the GABRA1,
GABRB2, and GABRG2 genes, respectively. Various mutations in
these genes impair channel gating and/or reduced mRNA stability,
aberration in subunit folding and glycosylation which result in
abnormal receptor assembly and trafﬁcking.2–4* Corresponding author. Tel.: +60 3 7967 4702/4703/5725; fax: +60 3 7967 4791.
E-mail address: batoolsadat@yahoo.com (B.S. Haerian).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.10.007The GABRG2 gene is located in 5q34 and is highly expressed in
the brain.5 Studies have suggested that mutations such as R43Q,
Q40X, K289M, and IVS6+2T in this gene are involved in childhood
absence epilepsy (CAE), febrile seizures (FS), generalized epilepsy
with febrile seizures plus (GEFS+), and Dravet syndrome.6,7
Previous studies examined whether the 588C>T Asn196Asn exon
5 polymorphism (rs211037) is related to susceptibility to FS or
idiopathic generalized epilepsy (IGE) in different populations,
however the results were inconsistent (Table 1 and Fig. 1).10–18 To
shed light on the association between rs211037 and susceptibility
to epilepsy, we carried out a systematic review and meta-analysis.
2. Methods
2.1. Search strategy and selection
This meta-analysis was performed based on the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.19 Articles were sought by using the MeSH
terms ‘‘epilepsy,’’ ‘‘polymorphism,’’ ‘‘variant,’’ ‘‘GABRG2,’’
‘‘rs211037,’’ ‘‘rs211037 C>T,’’ ‘‘Crs211037T,’’ and ‘‘susceptibility,’’vier Ltd. All rights reserved.
Table 1
Allele and genotype distribution of GABRG2 rs211037 polymorphism in the included studies.
No. Author Year Origin Epilepsy Deﬁnition
of epilepsy
Category Samples
(N)
Genotypes Alleles
(N)
Ass. Ref.
C/C C/T T/T C T
P C P C P C P C P C P C
1 Kananura et al. 2002 German IAE ILAE IGE 135 154 83 104 47 42 5 8 213 250 57 58 No 11
2 Madia et al. 2003 Italian SMEI
(FS + AFS)
ILAE All types 53 96 28 48 21 40 4 8 77 136 29 56 No 12
3 Chou et al. 2003 Taiwanese FS ILAE FS 104 83a 17 9 55 32 31 42 89 50 117 116 Yes 13
4 Nakayama et al. 2003 Japanese FS Freeman
JM, 1980
FS 94 106 24 23 50 58 20 25 98 104 90 108 No 14
5-1 Kinirons et al. 2006 British All ILAE All types 569 330 342 203 187 114 40 13 871 520 267 140 No 15
5-2 Kinirons et al. 2006 British FS ILAE FS 84 330 46 203 35 114 3 13 127 520 41 140 No 15
5-3 Kinirons et al. 2006 British IGE ILAE IGE 78 330 48 203 24 114 6 13 120 520 36 140 No 15
5-4 Kinirons et al. 2006 Irish All ILAE All types 699 283 376 170 262 99 31 14 1014 439 324 127 No 15
5-5 Kinirons et al. 2006 Irish FS Other FS 80 283 43 170 35 99 2 14 121 439 39 127 No 15
5-6 Kinirons et al. 2006 Irish IGE ILAE IGE 117 283 67 170 48 99 2 14 182 439 52 127 No 15
6 Ma et al. 2006 American Focal
epilepsy
with FS
Not
identiﬁed
FS 74 118 73 113 1 5 0 0 147 231 1 5 No 16
7 Chou et al. 2007 Taiwanese IGE ILAE IGE 77 83a 17 9 38 32 22 42 72 50 82 116 No 17
8 Salam et al. 2011 Egyptian Generalized
epilepsy
with FS
ILAE FS 100 120 26 12 42 46 32 62 94 70 106 170 Yes 18
Abbreviations: IAE, idiopathic absence epilepsy; SMEI, severe myoclonic epilepsy of infancy; FS, febrile seizure; GS, generalized seizure; IGE, idiopathic generalized epilepsy;
AFS, afebrile seizure; P, patient; C, control; ILAE, International League Against Epilepsy.
a Samples were the same.
B.S. Haerian, L. Baum / Seizure 22 (2013) 53–5854in MEDLINE, Embase, and the Cochrane Database of Systematic
Reviews without language limitation, the last search being updated
in July 2012. The reference lists were hand searched for other
relevant publications. Studies that determined the distribution of
the GABRG2 rs211037 genotype in unrelated epilepsy patients and
healthy controls were eligible for inclusion in the meta-analysis.
2.2. Data extraction
Publications were eligible for meta-analysis if they met the
following inclusion criteria: (a) study had been done in epilepsy
patients and controls; (b) genotype frequency data were available
for both case and control groups; and (c) genotype distribution
complied with Hardy–Weinberg equilibrium (after retesting in
this meta-analysis). Major exclusion criteria were as follows:Fig. 1. The rs211037 polymorphism is locat(a) controls were related to patients; (b) data duplicated those of
previous publications. The following characteristics were collected
from each study: ﬁrst author’s surname, year of publication,
ethnicity of patients, numbers of epilepsy patients and of controls
with each genotype, and type of epilepsy.
2.3. Statistical analysis
The per-allele odds ratios (OR) of the rare allele (T) as well as the
corresponding 95% conﬁdence intervals (CI) and p values were
calculated to compare epilepsy patients and controls. Codominant
(C/C vs. T/T and C/T vs. T/T), dominant (C/C + C/T vs. T/T), and
recessive (C/C vs. C/T + T/T) models were also tested. Subsidiary
meta-analyses were performed to evaluate the above models on
FS, IGE, or all studies. To measure the strength of geneticed within exon 5 of the GABRG2 gene.
27 Exc luded since unrelate d to epilepsy or to th is locus
1 Gene locat ion
1 Gene function
25 Other disorde rs
8 Incl uded in meta -analysis
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2 Pharmacogeno mics study
6 Family stu dy
2 No  control s
3 Review
1 Other po lymorph ism
1 Dupli cated data
1 Not  in Har dy-Weinberg Equ ilibrium
51 Abstracts retrieved for e valuat ion
24 Full-te xt  articles retrieved for e valuat ion
Fig. 2. Selection of studies of the GABRG2 rs211037 polymorphism.
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statistical heterogeneity, and the Q-statistic test with p < 0.1 was
used to deﬁne a signiﬁcant degree of heterogeneity. The double of
the usual signiﬁcance threshold (2  0.05) has been considered for
the Q-statistic test to increase the power of the heterogeneity test
in meta-analysis. Fixed-effects summary measures were calculat-
ed as inverse-variance-weighted averages of the log OR if there
was no heterogeneity (p > 0.1) and random-effects where sub-
stantial heterogeneity (p < 0.1) existed. Sensitivity analyses were
performed to assess the stability of the results of the meta-analysis.
All probability values are 2-sided, and values of p < 0.05
were considered statistically signiﬁcant. Statistical analyses
were performed using validated Meta-analysis Made Easy (MIX)
version 1.7.20Table 2
Meta-analysis of GABRG2 rs211037 and susceptibility to FS, IGE, and all epilepsies und
Allele/genotype FS (N = 6) IGE (N = 4) 
OR 95% CI p I2 (%) phet OR 95% CI 
T vs. C
All 0.77 (0.54–1.11) 0.16 71 <0.01 0.90 (0.63–1.2
Asian 0.62 (0.42–0.90) 0.01 63 0.07 – 
Caucasian – – – – 1.07 (0.86–1.3
TT vs. CC
All 0.47 (0.30–0.73) 0.0008 29 0.22 0.64 (0.25–1.6
Asian 0.41 (0.25–0.68) 0.0004 50 0.14 – 
Caucasian – – – – 1.01 (0.51–1.9
TT vs. CT
All 0.59 (0.42–0.83) 0.003 0 0.57 0.65 (0.28–1.5
Asian 0.59 (0.41–0.86) 0.005 23 0.27 – 
Caucasian – – – – 0.78 (0.24–2.5
TT vs. CC + CT
All 0.54 (0.39–0.75) 0.0002 0 0.43 0.67 (0.29–1.5
Asian 0.52 (0.37–0.74) 0.0003 37 0.20 – 
Caucasian – – – – 0.98 (0.50–1.9
CT + TT vs. CC
All 0.79 (0.48–1.28) 0.33 64 0.02 1.04 (0.80–1.3
Asian 0.56 (0.36–0.85) 0.007 43 0.17 – 
Caucasian – – – – 1.14 (0.87–1.5
Abbreviations: FS, febrile seizure; IGE, idiopathic generalized epilepsy.
a Since the control samples of Chou et al.12 and Chou et al.16 were the same, only o3. Results
Characteristics of the included studies are listed in Table 1. The
initial search with the keywords and the subject terms identiﬁed 51
abstracts, all published in English. Of these abstracts, 27 were
excluded because they were irrelevant to rs211037 or to epilepsy. In
the next step, the full texts of the 24 remaining articles were
evaluated, yielding eight, including 3258 subjects (1871 epilepsy
patients and 1387 controls) that met our eligibility criteria for meta-
analysis (Fig. 2). Amongst the included studies, only three reports—
two Taiwanese13,17 and one Egyptian18—were associated with
susceptibility to FS or IGE.
There was a considerable diversity of epilepsy types among the
eight included studies.11–18 The control group in the Taiwaneseer alternative genetic models.
All epilepsies (N = 8)a
p I2 (%) phet OR 95% CI p I
2 (%) phet
9) 0.57 68 0.03 0.79 (0.56–1.11) 0.17 85 <0.01
– – – 0.54 (0.33–0.87) 0.01 81 <0.01
5) 0.54 0 0.84 1.1 (0.95–1.28) 0.19 0 0.75
5) 0.36 63 0.04 0.62 (0.30–1.28) 0.20 83 <0.01
– – – 0.31 (0.13–0.74) 0.009 76 0.02
9) 0.98 44 0.17 1.21 (0.81–1.82) 0.36 0 0.44
1) 0.32 59 0.06 0.80 (0.61–1.05) 0.11 40 0.13
– – – 0.63 (0.44–0.90) 0.01 0 0.45
2) 0.67 63 0.07 1.11 (0.73–1.68) 0.64 31 0.22
4) 0.35 63 0.05 0.74 (0.45–1.20) 0.22 69 <0.01
– – – 0.49 (0.29–0.83) 0.008 58 0.09
1) 0.95 54 0.11 1.16 (0.75–1.78) 0.51 10 0.34
6) 0.75 39 0.18 0.72 (0.47–1.11) 0.14 83 <0.01
– – – 0.4 (0.2–0.8) 0.01 74 0.02
0) 0.35 0 0.76 1.11 (0.93–1.33) 0.24 0 0.66
ne control group was included in this meta-analysis.
Stud y Year OR rando m eff ects 95 % CI
Kananu ra et  al. 200 2 1.15  (0.77  t o  1.74 )
Chou  et  al. 2003 /200 7 0.39  (0.29  t o  0.53 )
Mad ia et  al. 200 3 0.91  (0.54  t o  1.55 )
Nakayama et  al. 200 3 0.88  (0.6  to  1.31 )
Kiniron s et  al.  (B) 200 6 1.14  (0.9  to  1.44 )
Kiniron s et  al.  (I) 200 6 1.1 (0.87  t o  1.4)
Ma et  al. 200 6 0.31  (0.04  t o  2.72 )
Salam et  al. 201 1 0.46  (0.31  t o  0.69 )
META-ANALYS IS: 0.79  (0.56  to 1.11 )
0.01 0.1 1 10
OR (log  sca le)
Fig. 3. Meta-analysis of the association of the T vs. C allele of rs211037 with all epilepsies. Since the control samples of two Chou et al. studies12,16 were the same, only one
control group was included in this meta-analysis. For each study, the position of the square is the OR, the horizontal line spans the 95% CI of the OR, and the area of the square
is inversely proportional to the variance of the log OR. The position of the diamond is the overall OR, and the horizontal span of the diamond represents the 95% CI of the OR. B,
British; I, Irish.
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studies was included in the meta-analysis of all studies (Table 2
and Fig. 3).13,17 Studies were classiﬁed into two categories: FS (6
studies: 535 patients vs. 1040 controls)13–16,18 and IGE (4 studies:
407 patients vs. 850 controls).15–7 In one report, patients had either
FS or IGE, hence that study was split and included in either FS or
IGE meta-analyses.15
Meta-analysis data of FS, IGE, and all studies are shown in Table
2. Neither allele nor genotype association was observed with IGE or
with all epilepsy (Table 2 and Fig. 3). However, signiﬁcant
association with FS existed under codominant (Fig. 4, TT vs. CC,
OR 0.47, 95% CI 0.30–0.73, p = 0.0008 and TT vs. CT, OR 0.59, 95% CI
0.42–0.83, p = 0.003) and dominant (OR 0.54, 95% CI 0.39–0.75,
p = 0.0002) genotype models. A sensitivity analysis which exclud-
ed each study in turn demonstrated an increase of the pooled OR
from 0.47 to 0.63 (TT vs. CC), 0.59 to 0.67 (TT vs. CT), and 0.54 to
0.82 (TT vs. CC + CT) and eliminated the signiﬁcance of the
associations (95% CI 0.37–1.06, p = 0.08; 95% CI 0.45–1.02, p = 0.06;
and 95% CI 0.47–1.41, p = 0.47, respectively) when the EgyptianStud y Year 
Chou  et  al. 200 3 
Nakayama et  al. 200 3 
Kiniron s et  al.  (B) 200 6 
Kiniron s et  al.  (I) 200 6 
Salam et  al. 201 1 
META-ANALYS IS: 
0.1 1 
OR (log  sc 
Fig. 4. Meta-analysis of the association of the TT vs. CC genotype of rs211037 with febrile s
the 95% CI of the OR, and the area of the square is inversely proportional to the variance o
the diamond represents the 95% CI of the OR. B, British; I, Irish.(for TT vs. CC or dominant) or Taiwanese study (for TT vs. CT or
dominant) was excluded. Therefore, signiﬁcant association in FS
meta-analysis was caused by the large effect size of these two
studies.
Sub-analysis by ethnicity was carried out for FS, IGE, and all
epilepsies. The number of Caucasian studies in FS or Asian studies in
IGE categories was not enough to do subgroup meta-analysis. No
allele or genotype association with IGE was seen in Caucasians or all
studies. However, there was signiﬁcant allele association with FS in
Asians (T vs. C, OR 0.62, 95% CI 0.42–0.90, p = 0.01). Additionally,
genotype association with FS was observed in codominant (TT vs. CC,
OR 0.41, 95% CI 0.25–0.68, p = 0.0004 and TT vs. CT, OR 0.59, 95% CI
0.41–0.86, p = 0.005), dominant (OR 0.52, 95% CI 0.37–0.74,
p = 0.0003), and recessive (OR 0.56, 95% CI 0.36–0.85, p = 0.007)
models. Altogether, the effect size of the Egyptian and Taiwanese FS
studies in the Asian sub-group resulted in signiﬁcant association not
only in Asians, but also in all epilepsies.
There was signiﬁcant heterogeneity for FS in the allele (all
studies, I2 = 71%, p < 0.01 and Asian studies, I2 = 63%, p = 0.07) andOR fixed eff ect 95 % CI
0.39  (0.15  t o  0.99 )
0.77  (0.34  t o  1.74 )
1.02  (0.28  t o  3.72 )
0.56  (0.12  t o  2.58 )
0.24  (0.11  t o  0.53 )
0.47  (0.3 to 0.73 )
10
ale)
eizures. For each study, the position of the square is the OR, the horizontal line spans
f the log OR. The position of the diamond is the overall OR, and the horizontal span of
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the IGE category, heterogeneity was signiﬁcant in the allele (all
studies, I2 = 68%, p = 0.03), codominant (TT vs. CC, all studies, I2 = 63%,
p = 0.04; TT vs. CT, all studies, I2 = 59%, p = 0.06; Caucasian studies,
I2 = 63%, p = 0.07) and dominant (all studies, I2 = 63%, p = 0.05)
models (Table 2). The funnel plot for T vs. C in all studies was basically
symmetric, and Egger’s test did not indicate statistically signiﬁcant
asymmetry of the plot (intercept = 1.85, 95% CI 7.68–3.97,
p = 0.47), suggesting no evidence of publication bias.
4. Discussion
Of eight reports, three supported the hypothesis that the
synonymous GABRG2 rs211037 polymorphism is a risk factor for
epilepsy: one study in Egypt for susceptibility to FS and two studies
in Taiwan for susceptibility to FS or IGE. Meta-analysis showed
signiﬁcant association between rs211037 and FS under co-dominant
and dominant genotype models, with the Egyptian and/or
Taiwanese studies contributing much of the signiﬁcance. However,
meta-analysis did not show signiﬁcant association between IGE and
either alleles or genotypes. It is plausible that the association with FS
is either a true positive or a false positive obtained by chance.
Ethnicity might explain the association with FS. The prevalence
of variants and linkage disequilibrium with other risk-associated
variants varies among geographical populations. This genetic
difference interacts with environmental factors such as regional
climate, culture, and pathogens and results in a variety of
adaptations of populations or individuals.21–23 The incidence of
FS varies in the world. In Western Europe and USA, the incidence of
FS is less than Asia (2–5% vs. 5–10% in India, and 9% in Japan).24 In
this study, the CC genotype in the Asians with FS was more
frequent than in controls (23 and 14%, respectively), while it did
not differ between Caucasians with FS and controls (44 and 45%,
respectively). It is possible that the CC genotype acts as a causal
factor for susceptibility to FS in Asians (Chinese and Egyptians) but
not in Caucasians due to differences in environment, genetic
background, or linkage disequilibrium of rs211037 with other
variants contributing to epilepsy risk. Veriﬁcation of this ﬁnding
awaits future studies.
On the other hand, the results of the Taiwanese and Egyptian FS
studies may be false due to small sample size and uncontrolled
genotyping quality phenomena. Sample size is a crucial determi-
nant of the power to detect a causal variant in genetic association
studies of multi-factorial polygenic diseases. To increase the power
of these studies, large sample sizes are needed to give enough
power for identifying the common causal loci with small effect
sizes.25,26 The range of sample sizes within the 6 FS association
studies was 187–414 (mean = 263). Of the two FS studies with
signiﬁcant association, one had the minimum subject number
(187) and the other had less than the average sample size
(220).13,18 Rigorous quality control (QC) is a crucial component of
association studies since subtle biases in raw data can produce
false positives.27 In the FS group, the three studies with signiﬁcant
association used the same method and protocol for genotype
analysis (polymerase chain reaction-restriction fragment length
polymorphism or PCR-RFLP),13,17,18 while the studies with
opposite results used single-strand conﬁrmation polymorphism
(SSCP) analysis or Applied Biosystems Taqman technology.14–16
The three articles with signiﬁcant association did not state
whether they controlled the PCR-RFLP product quality by other
techniques, however the studies that used SSCP or Taqman
technology duplicated some genotype data by other techniques. A
replication stage using alternative standard methods is a key factor
in controlling genotype quality and reducing false positive
results.27 However, despite of doing QC for genotyping; the error
of some techniques such as SSCP cannot be ignored. For example, astudy which was performed in European American samples,
reported a very low frequency of minor allele frequency in both
cases and controls (0.007 and 0.02, respectively).16
Some limitations of our meta-analysis should be acknowledged.
First, the criteria for the selection of patients and controls in the
included studies were heterogeneous for parameters such as
deﬁnitions for FS, seizure type, and family history of FS. There are
two deﬁnitions of FS, published by the National Institute of Health
(NIH) and the International League Against Epilepsy (ILAE). The NIH
and ILAE deﬁnitions are very similar, but they differ in the lower age
limit (three vs. one month, respectively).24 Among the six studies of
FS, four used the ILAE deﬁnition of FS.13,15,18 Seizures are a clinical
component of FS and consist of two different types: simple
(generalized tonic–clonic) and complex (focal).28 Of the FS studies,
three were carried out on patients with simple FS18 and all or 90%16
of patients with complex FS,14 respectively, but the remaining
studies did not identify the type of seizure in the FS patients. Positive
family history for FS increases the risk of developing FS up to 25–40%,
as compared with acquired FS. Because the molecular mechanisms
of familial FS differ from those of acquired FS, a heterogeneous
population composed of both hereditary and nonhereditary FS
produces underpowered results.29 Out of six FS studies, three
reported positive family history of FS in 28.5%,18 86%,14 and 100% of
FS patients,16 but the remaining studies did not report the family
history of FS patients. Second, the small number of studies of
Caucasians with FS and Asians with IGE made it impossible to
perform a complete stratiﬁed analysis by ethnicity. Third, the two
Taiwanese studies used the same controls in their analysis. In
conclusion, despite signiﬁcant association between the GABRG2
rs211037 polymorphism and susceptibility to FS, a possible false
positive result cannot be excluded. Future studies with larger
sample sizes are required to verify the results.
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